{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:13:24Z","timestamp":1760987604649,"version":"build-2065373602"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10072-025-08354-w","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:20:42Z","timestamp":1753352442000},"page":"5279-5286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Central nervous system demyelination associated with biological agents used in the treatment of rheumatologic diseases: a retrospective cohort study"],"prefix":"10.1007","volume":"46","author":[{"given":"Doruk","family":"Arslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basak","family":"Sayinalp-Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Acar-Ozen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahsan","family":"Gocmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-4483","authenticated-orcid":false,"given":"Asli","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"2","key":"8354_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","volume":"17","author":"V Strand","year":"2021","unstructured":"Strand V, Goncalves J, Isaacs JD (2021) Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 17(2):81\u201397. https:\/\/doi.org\/10.1038\/s41584-020-00540-8","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"8354_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0889-857x(07)70003-0","volume":"32","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Kavanaugh A (2006) Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am 32(Suppl 1):3\u201310. https:\/\/doi.org\/10.1016\/s0889-857x(07)70003-0","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"8354_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E (2017) CNS Demyelination with TNF-\u03b1 Blockers. Curr Neurol Neurosci Rep 17(4):36. https:\/\/doi.org\/10.1007\/s11910-017-0742-1","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"8354_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"2","key":"8354_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729","journal-title":"Neurology"},{"issue":"3","key":"8354_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/s1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"issue":"8","key":"8354_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/s1474-4422(10)70135-6","volume":"9","author":"RA Marrie","year":"2010","unstructured":"Marrie RA, Horwitz RI (2010) Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 9(8):820\u2013828. https:\/\/doi.org\/10.1016\/s1474-4422(10)70135-6","journal-title":"Lancet Neurol"},{"issue":"4","key":"8354_CR8","doi-asserted-by":"publisher","first-page":"e24294","DOI":"10.7759\/cureus.24294","volume":"14","author":"Z Barkhane","year":"2022","unstructured":"Barkhane Z, Elmadi J, Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S (2022) Multiple Sclerosis and Autoimmunity A Veiled Relationship. Cureus 14(4):e24294. https:\/\/doi.org\/10.7759\/cureus.24294","journal-title":"Cureus"},{"key":"8354_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jns.2017.01.023","volume":"373","author":"P Barreras","year":"2017","unstructured":"Barreras P, Mealy MA, Pardo CA (2017) TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. J Neurol Sci 373:303\u2013306. https:\/\/doi.org\/10.1016\/j.jns.2017.01.023","journal-title":"J Neurol Sci"},{"issue":"1","key":"8354_CR10","doi-asserted-by":"publisher","first-page":"205521732110707","DOI":"10.1177\/20552173211070750","volume":"8","author":"SY Chey","year":"2022","unstructured":"Chey SY, Kermode AG (2022) Central nervous system demyelination related to tumour necrosis factor alpha inhibitor. Mult Scler J Exp Transl Clin 8(1):20552173211070750. https:\/\/doi.org\/10.1177\/20552173211070750","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"8354_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","volume":"40","author":"MC Fern\u00e1ndez-Espartero","year":"2011","unstructured":"Fern\u00e1ndez-Espartero MC, P\u00e9rez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, G\u00f3mez-Reino JJ et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40(4):330\u2013337. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.06.004","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"8354_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P et al (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 16(11):1255\u20131271. https:\/\/doi.org\/10.1080\/14740338.2017.1372421","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"8354_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18847","volume":"13","author":"M Zahid","year":"2021","unstructured":"Zahid M, Busmail A, Penumetcha SS, Ahluwalia S, Irfan R, Khan SA et al (2021) Tumor Necrosis Factor Alpha Blockade and Multiple Sclerosis: Exploring New Avenues. Cureus 13(10):e18847. https:\/\/doi.org\/10.7759\/cureus.18847","journal-title":"Cureus"},{"key":"8354_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev.iy.10.040192.001101","volume":"10","author":"R Martin","year":"1992","unstructured":"Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153\u2013187. https:\/\/doi.org\/10.1146\/annurev.iy.10.040192.001101","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"8354_CR15","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1212\/wnl.0000000000201472","volume":"100","author":"L Li","year":"2023","unstructured":"Li L, Avi\u00f1a-Zubieta JA, Bernstein CN, Kaplan GG, Tremlett H, Xie H et al (2023) Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 canadian provinces: a population-based study. Neurology 100(6):e558\u2013e567. https:\/\/doi.org\/10.1212\/wnl.0000000000201472","journal-title":"Neurology"},{"issue":"12","key":"8354_CR16","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12\/3c2862::aid-art474\/3e3.0.co;2-w","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862\u20132869. https:\/\/doi.org\/10.1002\/1529-0131(200112)44:12\/3c2862::aid-art474\/3e3.0.co;2-w","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8354_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4274\/tnd.2020.36418","volume":"27","author":"\u00dc T\u00fcrkB\u00f6r\u00fc","year":"2021","unstructured":"T\u00fcrkB\u00f6r\u00fc \u00dc, B\u00f6l\u00fck C, Tasdemir M, Gezer T (2021) Epidemiology of multiple sclerosis in Turkey; a ten-year trend in rural cities. T\u00fcrk N\u00f6roloji Dergisi 27(1):41\u201345. https:\/\/doi.org\/10.4274\/tnd.2020.36418","journal-title":"T\u00fcrk N\u00f6roloji Dergisi"},{"issue":"7","key":"8354_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/13524585241245318","volume":"30","author":"B \u00d6zt\u00fcrk","year":"2024","unstructured":"\u00d6zt\u00fcrk B, Ta\u015fk\u0131ran E, Demir S, Tuncer MA, K\u00fcrt\u00fcnc\u00fc M, Karabudak R et al (2024) Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study. Mult Scler 30(7):790\u2013799. https:\/\/doi.org\/10.1177\/13524585241245318","journal-title":"Mult Scler"},{"issue":"3","key":"8354_CR19","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1212\/nxi.0000000000000992","volume":"8","author":"TRP Taylor","year":"2021","unstructured":"Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R (2021) Demyelinating Events Following Initiation of Anti-TNF\u03b1 Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm 8(3):e992. https:\/\/doi.org\/10.1212\/nxi.0000000000000992","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"8354_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1468-1331.2006.01342.x","volume":"13","author":"M Pugliatti","year":"2006","unstructured":"Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, V\u00e9csei L et al (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13(7):700\u2013722. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01342.x","journal-title":"Eur J Neurol"},{"key":"8354_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577587","volume":"356","author":"SK Hutto","year":"2021","unstructured":"Hutto SK, Rice DR, Mateen FJ (2021) CNS demyelination with TNF\u03b1 inhibitor exposure: A retrospective cohort study. J Neuroimmunol 356:577587. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577587","journal-title":"J Neuroimmunol"},{"issue":"8","key":"8354_CR22","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1111\/ijd.14902","volume":"59","author":"M Megna","year":"2020","unstructured":"Megna M, Marasca C, Ruggiero A, Camela E, Fabbrocini G (2020) Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? Int J Dermatol 59(8):e308\u2013e309. https:\/\/doi.org\/10.1111\/ijd.14902","journal-title":"Int J Dermatol"},{"issue":"6","key":"8354_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/imt-2021-0128","volume":"14","author":"MA Eksin","year":"2022","unstructured":"Eksin MA, Erden A, G\u00fcven SC, Armagan B, Ozdemir B, Karakas O et al (2022) Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review. Immunotherapy 14(6):401\u2013408. https:\/\/doi.org\/10.2217\/imt-2021-0128","journal-title":"Immunotherapy"},{"issue":"1","key":"8354_CR24","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/ajd.13983","volume":"64","author":"M Megna","year":"2023","unstructured":"Megna M, Noto M, Fabbrocini G, Fornaro L (2023) A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab. Australas J Dermatol 64(1):e100\u2013e102. https:\/\/doi.org\/10.1111\/ajd.13983","journal-title":"Australas J Dermatol"},{"issue":"3","key":"8354_CR25","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar4582","volume":"16","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA (2014) Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16(3):R125. https:\/\/doi.org\/10.1186\/ar4582","journal-title":"Arthritis Res Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08354-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T03:15:26Z","timestamp":1759288526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08354-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["8354"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08354-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from both local (Hacettepe University-KA22005) and national (23-AKD-65) ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed\u00a0consent was obtained from all participants, according to the Helsinki declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}